Quality Risk Assessment in Pharmaceutical Industry | CPhI North America

CPhI North America is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

 

View, browse and sort the ever-growing list of sessions by pass type, track, and format. With this Session Scheduler, you can build your schedule in advance and access it during the show via export or with the Mobile App, once live. Sessions do fill up and seating is first come, first serve, so arrive early to sessions that you would like to attend.

Quality Risk Assessment in Pharmaceutical Industry

Muhammad Naeem (Chief Operating Officer, Indus Pharma Pvt. Limited)

Location: E353c

Date: Tuesday, April 30

Time: 2:15pm - 3:00pm

Vault Recording: TBD

The use of multiproduct facilities for the production of pharmaceutical products is need of time to allow products to be brought to patients in a timely and cost-effective manner. Doing this safely requires an understanding of the products, the facilities, the processes, and the equipment and the risks posed by this combination. The major risk of concern within shared facilities is the risk of cross-contamination. New GMP guidance for the EU came into effect in 2015 that requires a risk management process to determine if products can be safely manufactured in shared facilities. This new GMP requirement left industry unsure how to perform and document these risk assessments.

The user must understand the relationship of hazard, exposure, and risk. If done properly, the stakeholders should be able to demonstrate a full understanding of the processes being evaluated. A consistent approach across the hazard continuum is integral in this approach so that the regulators can be confident that a well thought out plan to reduce risk to an acceptable level has been established. Professionals in the pharmaceutical industry should move forward with a consistent approach on setting acceptable limits to assess the potential of cross-contamination causing an undue risk to patient safety. This approach is intended to enable manufacturers to implement appropriate controls to facilitate safe and affordable drug product manufacturing without complicating the engineering solutions

It has become clear that in the pharmaceutical sector, an adequate risk management system is not only required by regulatory stakeholders but may also result in a competitive advantage when appropriately implemented. Hence, to be prepared for future challenges, more predictive and proactive strategies towards product and process development, quality assurance and quality control, product life-cycle management and business operations in general are required. Risk management can be seen of one major aspect of these approaches with the goal to facilitate innovation and Continuous Improvement. The chosen system in quality management represent major aspects of the pharmaceutical quality assurance system and their enhancement with regard to risk management can be well used as primer for further integration activities.

It is important to have an escalation process that allows management to be informed of areas that have risk that is unacceptable or near unacceptable. The holistic approach that is described in this session is predicated on the fact that all of those involved have received appropriate education and training and have ready access to support risk assessment and management documentation.